SB 719 restricts the land application of sewage sludge containing per- and polyfluoroalkyl substances (PFAS) above specific concentration levels, effective after a set date. It requires monitoring for PFAS in sewage sludge and products containing it, authorizes stricter pretreatment rules for industrial users discharging PFAS, and allows local jurisdictions to set fees for such discharges. The bill directly affects sewage sludge generators (like wastewater treatment facilities), industrial users, and local regulators by mandating new PFAS testing, usage limits, and fee structures. It amends Maryland’s environmental code to establish these requirements without changing existing land application rules for sludge below the new PFAS thresholds.
HB 771 requires Maryland health occupations boards to allow license renewal credits for free, 1-hour human trafficking awareness training. The training must cover definitions of trafficking, trauma-informed care, health indicators, screening protocols, reporting requirements, and survivor resources. It directly affects health practitioners (like nurses and therapists) needing license renewals, with boards mandated to adopt regulations by October 2026. The Maryland Department of Health must approve the training program by July 2026 in collaboration with universities and anti-trafficking organizations. The bill takes effect June 1, 2026.
HB 1533 (the Crown and Care Act) bans 12 specific harmful ingredients - including certain phthalates, formaldehyde, mercury, and PFAS chemicals - from cosmetic products sold in Maryland. It directly affects cosmetic manufacturers, retailers, and salons by prohibiting the sale or distribution of products containing these ingredients, with limited exceptions for unavoidable trace amounts from manufacturing processes. The bill authorizes the Maryland Department of Health to investigate complaints, inspect businesses, and enforce penalties, while allowing consumers harmed by violations to seek civil damages and attorney fees. This law aims to protect public health by reducing exposure to chemicals linked to health risks like skin irritation and potential long-term harm.
SB 645 restructures Maryland's State Board of Sign Language Interpreters by expanding its membership from seven to 11 members with specific representation requirements, including a deafblind individual, deaf community members, licensed interpreters from various settings (legal, medical, educational), and ex-officio members from disability and labor agencies. The bill requires the Board to establish licensing requirements for sign language interpreters by December 31, 2026 (previously July 1, 2024), and mandates interpreters to meet these standards by that date. It also adds new grounds for the Governor to remove board members, including two consecutive unexcused absences or failing to attend 50% of meetings annually. These changes aim to improve board diversity, clarify licensing timelines, and ensure board members meet ongoing eligibility criteria.
HB 1135 allows pharmacists in Maryland to order certain vaccinations for patients aged 3 and older without needing to administer the vaccine themselves. Pharmacists must complete 20+ hours of approved training covering vaccine safety, injection techniques, and emergency response, hold current CPR certification, and report all vaccinations to the ImmuNet program. The bill specifically covers influenza, COVID-19, and emergency-use vaccines, and requires pharmacists to refer minors to pediatric care when ordering vaccines. This expands pharmacists' role in vaccine access while maintaining safety protocols and reporting requirements.
SB 773 allows pharmacists in Maryland to order certain vaccinations (like flu, COVID-19, or emergency vaccines) for patients aged 3 and older without needing to administer the vaccine themselves. To qualify, pharmacists must complete 20 hours of approved training, hold current CPR certification, and complete 2 hours of continuing education on immunizations. The bill requires pharmacists to follow written vaccine-specific protocols, report all vaccinations to Maryland’s ImmuNet registry, and refer pediatric patients to primary care providers when appropriate. This policy directly affects pharmacists, patients seeking these vaccines, and healthcare coordination for immunizations. The changes take effect October 1, 2026.
SB 778 creates a new "clinical research pharmacy permit" required for pharmacies conducting clinical trials in Maryland. It allows healthcare providers to own such pharmacies under specific conditions, including requiring a licensed pharmacist to be on-site at all times and prohibiting owners from receiving payment for patient referrals. The bill also exempts clinical trials conducted by corporations from being classified as "practice of medicine," removing a licensing barrier for these activities. This directly affects pharmacies seeking to operate clinical trials, healthcare providers considering ownership, and the State Board of Pharmacy (as the permit issuer).
SB 159 requires Maryland's Emergency Medical Services (EMS) providers to maintain specific equipment and supplies on ambulances, including neonatal care items, and mandates quarterly reviews of performance data like response times and service quality. It also requires counties to establish formal, accessible complaint systems for ambulance quality or conduct issues, with online and in-person filing, tracking, and quarterly reporting to the state EMS Institute. These provisions directly affect all counties and municipalities operating or contracting EMS services, as well as the Maryland Institute for EMS Systems, which coordinates the statewide standards. The bill aims to standardize ambulance equipment, improve accountability through data reviews, and enhance patient access to complaint resolution. It takes effect July 1, 2026.
SB 96 updates terminology in Maryland's Sheila E. Hixson Behavioral Health Services Matching Grant Program by removing the word "active" before "service member" throughout the law. This change clarifies that the program serves all service members (including those not currently on active duty), veterans, and their families, without altering eligibility criteria or funding. The bill specifically revises definitions in Section 7.5-210(a)(2)(i), (b)(2), and (e)(1)(ii) to replace "active service member" with "service member." It does not create new benefits or change who qualifies for grants, only how the program describes its target population. The change aims to align the law with the program's actual scope and improve clarity.
HB 446 establishes the Dementia Services and Brain Health Program within Maryland’s Department of Health to lead state public health efforts on brain health and dementia. The program replaces the previous "Director" role for key duties, including staffing the Virginia I. Jones Alzheimer’s Disease and Related Dementias Council and overseeing implementation of the State Plan on Alzheimer’s and related dementias. It requires the program, in partnership with the Department of Aging and other entities, to develop a clinical toolkit for healthcare providers to improve dementia care. The bill updates existing law to formalize this program structure and its responsibilities.
